Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
Wen OuyangJing YuYan ZhouJing HuZhao HuangJunhong ZhangConghua XiePublished in: BMC cancer (2020)
Patients developing metachronous BM during EGFR-TKIs treatment have worse outcomes. Our results suggested that EGFR-mutated advanced NSCLC patients with ≥1 risk factors were candidates for PCI or the first-line Osimertinib treatment.
Keyphrases
- percutaneous coronary intervention
- small cell lung cancer
- acute coronary syndrome
- antiplatelet therapy
- coronary artery disease
- risk factors
- coronary artery bypass grafting
- epidermal growth factor receptor
- tyrosine kinase
- atrial fibrillation
- heart failure
- single cell
- stem cells
- type diabetes
- resting state
- cell therapy
- cerebral ischemia